Clinical Trial Update: Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating nimotuzumab with neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma; the current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Esophageal Squamous Cell Carcinoma Resectable | Phase 2 | Status: UNKNOWN